Literature DB >> 30674718

Adaptive NK cell reconstitution is associated with better clinical outcomes.

Frank Cichocki1, Emily Taras1, Flavia Chiuppesi2, John E Wagner3, Bruce R Blazar3, Claudio Brunstein1, Xianghua Luo4,5, Don J Diamond2, Sarah Cooley1, Daniel J Weisdorf1, Jeffrey S Miller1.   

Abstract

BACKGROUND: Human cytomegalovirus (CMV) reactivation is a common occurrence early after transplant and is associated with heterogeneous NK cell subset expansion. These adaptive NK cell expansions are highly variable between recipients, with respect to magnitude and relative frequencies of adaptive NK cell subsets.
METHODS: To gain insight into the factors that influence adaptive NK cell expansion from a CMV naive graft source, we performed a high-resolution NK cell and CD8+ T cell phenotypic analysis of 215 patients with hematological malignancies that were transplanted with 2 partially HLA matched CMV negative umbilical cord blood units.
RESULTS: We found that adaptive NK cells were significantly higher in recipients who received nonmyeloablative conditioning (NMAC) relative to myeloablative conditioning (MAC), and high CMV neutralizing antibody titers correlated with the degree of adaptive NK cell expansion. The frequencies of adaptive NK cell subsets (defined by NKG2C, FcεRγ, EAT-2, and SYK expression) that reconstitute from donor hematopoietic progenitor cells largely matched the frequencies observed in the NK cell compartment of the recipient prior to conditioning, suggesting that host - as well as viral reactivation factors - may determine the phenotypic diversification after transplant. Additionally, multivariable analyses show that higher adaptive NK cell expansion associated with better disease-free survival.
CONCLUSIONS: Our findings provide important insights into adaptive NK cell reconstitution after transplant and support a role for adaptive NK cells in promoting better clinical outcomes. FUNDING: The NIH and the National Marrow Donor Program.

Entities:  

Keywords:  Bone marrow transplantation; Immunology; Leukemias; NK cells; Transplantation

Year:  2019        PMID: 30674718      PMCID: PMC6413795          DOI: 10.1172/jci.insight.125553

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  48 in total

1.  Effector memory T cells, early metastasis, and survival in colorectal cancer.

Authors:  Franck Pagès; Anne Berger; Matthieu Camus; Fatima Sanchez-Cabo; Anne Costes; Robert Molidor; Bernhard Mlecnik; Amos Kirilovsky; Malin Nilsson; Diane Damotte; Tchao Meatchi; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Jérôme Galon
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

2.  Differentiation of cytomegalovirus-specific CD8(+) T cells in healthy and immunosuppressed virus carriers.

Authors:  L E Gamadia; R J Rentenaar; P A Baars; E B Remmerswaal; S Surachno; J F Weel; M Toebes; T N Schumacher; I J ten Berge; R A van Lier
Journal:  Blood       Date:  2001-08-01       Impact factor: 22.113

3.  Long-term immune recovery of patients undergoing allogeneic stem cell transplantation: a comparison with their respective sibling donors.

Authors:  Fermin M Sanchez-Guijo; Luis-Ignacio Sanchez-Abarca; Clara Bueno; Eva Villaron; Natalia Lopez-Holgado; Lourdes Vazquez; Jesus Lopez-Fidalgo; Jose A Perez-Simon; Maria-Dolores Caballero; Maria-Consuelo del Cañizo; Alberto Orfao; Jesus F San Miguel
Journal:  Biol Blood Marrow Transplant       Date:  2005-05       Impact factor: 5.742

4.  Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors.

Authors:  Hisashi Arase; Edward S Mocarski; Ann E Campbell; Ann B Hill; Lewis L Lanier
Journal:  Science       Date:  2002-04-11       Impact factor: 47.728

5.  Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen.

Authors:  S Morecki; Y Gelfand; A Nagler; R Or; E Naparstek; G Varadi; D Engelhard; A Akerstein; S Slavin
Journal:  Bone Marrow Transplant       Date:  2001-08       Impact factor: 5.483

6.  Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution.

Authors:  D C Douek; R A Vescio; M R Betts; J M Brenchley; B J Hill; L Zhang; J R Berenson; R H Collins; R A Koup
Journal:  Lancet       Date:  2000-05-27       Impact factor: 79.321

7.  Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning.

Authors:  Michael Maris; Michael Boeckh; Barry Storer; Monja Dawson; Kristen White; Michael Keng; Brenda Sandmaier; David Maloney; Rainer Storb; Jan Storek
Journal:  Exp Hematol       Date:  2003-10       Impact factor: 3.084

8.  A comparison of T-, B- and NK-cell reconstitution following conventional or nonmyeloablative conditioning and transplantation with bone marrow or peripheral blood stem cells from human leucocyte antigen identical sibling donors.

Authors:  S L Petersen; L P Ryder; P Björk; H O Madsen; C Heilmann; N Jacobsen; H Sengeløv; L L Vindeløv
Journal:  Bone Marrow Transplant       Date:  2003-07       Impact factor: 5.483

9.  Recognition of a virus-encoded ligand by a natural killer cell activation receptor.

Authors:  Hamish R C Smith; Jonathan W Heusel; Indira K Mehta; Sungjin Kim; Brigitte G Dorner; Olga V Naidenko; Koho Iizuka; Hiroshi Furukawa; Diana L Beckman; Jeanette T Pingel; Anthony A Scalzo; Daved H Fremont; Wayne M Yokoyama
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-11       Impact factor: 11.205

10.  HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function.

Authors:  V Appay; D F Nixon; S M Donahoe; G M Gillespie; T Dong; A King; G S Ogg; H M Spiegel; C Conlon; C A Spina; D V Havlir; D D Richman; A Waters; P Easterbrook; A J McMichael; S L Rowland-Jones
Journal:  J Exp Med       Date:  2000-07-03       Impact factor: 14.307

View more
  27 in total

1.  The association of CMV with NK-cell reconstitution depends on graft source: results from BMT CTN-0201 samples.

Authors:  Armin Rashidi; Xianghua Luo; Sarah Cooley; Claudio Anasetti; Edmund K Waller; Claudio G Brunstein; Frank Cichocki; Daniel J Weisdorf; Jeffrey S Miller
Journal:  Blood Adv       Date:  2019-08-27

2.  Identifying the optimal donor for natural killer cell adoptive therapy to treat paediatric B- and T-cell acute lymphoblastic leukaemia.

Authors:  Bree Foley; Clara Ta; Samantha Barnes; Emma de Jong; Michelle Nguyen; Laurence C Cheung; Anthony Buzzai; Teagan Wagner; Ben Wylie; Sonia Fernandez; Mark Cruickshank; Raelene Endersby; Ursula Kees; Jason Waithman
Journal:  Clin Transl Immunology       Date:  2020-07-16

3.  A novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation.

Authors:  Li Li; Han Chen; David Marin; Yuanxin Xi; Qi Miao; Jiangxing Lv; Pinaki Prosad Banerjee; Hila Shaim; May Daher; Rafet Basar; Nobuhiko Imahashi; Juan Jimenez; Bingqian Hu; Rohtesh S Mehta; Lucila Nassif Kerbauy; Mecit Kaplan; Mayela Mendt; Gonca Ozcan; Elif Gokdemir; Mayra Hernandez Sanabria; Ye Li; Ken Chen; Jing Wang; Luis Muniz-Feliciano; Wei-Li Zhao; Richard E Champlin; Elizabeth J Shpall; Katayoun Rezvani
Journal:  Blood Adv       Date:  2019-12-10

Review 4.  Harnessing Natural Killer Cell Antitumor Immunity: From the Bench to Bedside.

Authors:  Karrune V Woan; Jeffrey S Miller
Journal:  Cancer Immunol Res       Date:  2019-11       Impact factor: 11.151

5.  Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy.

Authors:  Karrune V Woan; Hansol Kim; Ryan Bjordahl; Zachary B Davis; Svetlana Gaidarova; John Goulding; Brian Hancock; Sajid Mahmood; Ramzey Abujarour; Hongbo Wang; Katie Tuininga; Bin Zhang; Cheng-Ying Wu; Behiye Kodal; Melissa Khaw; Laura Bendzick; Paul Rogers; Moyar Qing Ge; Greg Bonello; Miguel Meza; Martin Felices; Janel Huffman; Thomas Dailey; Tom T Lee; Bruce Walcheck; Karl J Malmberg; Bruce R Blazar; Yenan T Bryceson; Bahram Valamehr; Jeffrey S Miller; Frank Cichocki
Journal:  Cell Stem Cell       Date:  2021-09-14       Impact factor: 25.269

6.  CMV Triplex Vaccine to Enhance Adaptive NK and T-cell Reconstitution After Autologous Hematopoietic Cell Transplantation.

Authors:  Armin Rashidi; Corinna La Rosa; Julie Curtsinger; Qing Cao; Qiao Zhou; Chetan Raj Lingaraju; Daniel J Weisdorf; Frank Cichocki; Jeffrey S Miller; Don J Diamond
Journal:  Transplant Cell Ther       Date:  2022-03-08

Review 7.  A Natural Impact: NK Cells at the Intersection of Cancer and HIV Disease.

Authors:  Olivier Lucar; R Keith Reeves; Stephanie Jost
Journal:  Front Immunol       Date:  2019-08-14       Impact factor: 7.561

Review 8.  An Historical Overview: The Discovery of How NK Cells Can Kill Enemies, Recruit Defense Troops, and More.

Authors:  Massimo Vitale; Claudia Cantoni; Mariella Della Chiesa; Guido Ferlazzo; Simona Carlomagno; Daniela Pende; Michela Falco; Annamaria Pessino; Letizia Muccio; Andrea De Maria; Emanuela Marcenaro; Lorenzo Moretta; Simona Sivori
Journal:  Front Immunol       Date:  2019-06-19       Impact factor: 7.561

Review 9.  Allogeneic Stem Cell Transplantation Platforms With Ex Vivo and In Vivo Immune Manipulations: Count and Adjust.

Authors:  Moniek de Witte; Laura G M Daenen; Lotte van der Wagen; Anna van Rhenen; Reiner Raymakers; Kasper Westinga; Jürgen Kuball
Journal:  Hemasphere       Date:  2021-06-01

10.  Anti-NKG2C/IL-15/anti-CD33 killer engager directs primary and iPSC-derived NKG2C+ NK cells to target myeloid leukemia.

Authors:  Emily Chiu; Martin Felices; Frank Cichocki; Zachary Davis; Hongbo Wang; Katie Tuninga; Daniel A Vallera; Tom Lee; Ryan Bjordahl; Karl Johan Malmberg; Bahram Valamehr; Jeffrey S Miller
Journal:  Mol Ther       Date:  2021-06-24       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.